

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for December 2023

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Mint Pharmaceuticals Inc.	Mint-Betahistine	SERC	BETAHISTINE DIHYDROCHLORIDE	8 mg	tablet	02538121
Mint Pharmaceuticals Inc.	Mint-Betahistine	SERC	BETAHISTINE DIHYDROCHLORIDE	16 mg	tablet	02538148
Mint Pharmaceuticals Inc.	Mint-Betahistine	SERC	BETAHISTINE DIHYDROCHLORIDE	24 mg	tablet	02538156
Jamp Pharma Corporation	Jamp Clobetasol Spray	Clobex Spray	CLOBETASOL PROPIONATE	0.05% w/w	topical spray	02534665
Altius Healthcare Inc	Dexlansoprazole	Dexilant	DEXLANSOPRAZOLE	30 mg	DR capsule	02536390

Altius Healthcare Inc	Dexlansoprazole	Dexilant	DEXLANSOPRAZOLE	60 mg	DR capsule	02536404
Sanis Health Inc.	Febuxostat	Uloric	FEBUXOSTAT	80 mg	tablet	02539837
Sanis Health Inc.	Pantoprazole	Pantoloc	PANTOPRAZOLE SODIUM	20 mg	DR tablet	02536137
Dr. Reddy's Laboratories Canada Inc.	Reddy-Sapropterin	Kuvan	SAPROPTERIN DIHYDROCHLORIDE	100 mg	powder for oral solution	02534533
Dr. Reddy's Laboratories Canada Inc.	Reddy-Sapropterin	Kuvan	SAPROPTERIN DIHYDROCHLORIDE	500 mg	powder for oral solution	02535610